Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Faroux

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2015
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†C Delbaldo, M Ychou, A Zawadi, et al.
Endoscopy|October 31, 2012
Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter studyS Nahon, H Hagège, J P Latrive, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2018
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancerT Aparicio, O Bouché, E Francois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2018
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study resultsT Aparicio, O Bouché, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study resultsT Aparicio, O Bouché, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2020
Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929F Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Plos One|December 21, 2020
PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancerL Mineur, E François, C Plassot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2015
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†C Delbaldo, M Ychou, A Zawadi, et al.
Endoscopy|October 31, 2012
Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter studyS Nahon, H Hagège, J P Latrive, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2018
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancerT Aparicio, O Bouché, E Francois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2018
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study resultsT Aparicio, O Bouché, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study resultsT Aparicio, O Bouché, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2020
Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929F Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Plos One|December 21, 2020
PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancerL Mineur, E François, C Plassot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Pageof 3